Citations

Clear

3042 citation(s) found for "Kumar, S".

Abstract A03: Krüppel-like Transcription Factor-10 (KLF10) suppresses the TGFβ-induced epithelial-to-mesenchymal transition
Kari, Vijayalakshmi, Subramaniam, Malayannan , Baumgart, Simon J., Nagarajan, Sankari , Spelsberg, Thomas C., Hawse, John R. , Mishra, Vivek Kumar , Wegwitz, Florian , Johnsen, Steven A.

Mayo Clinic

Cancer Research | May 20, 2016 | Volume: 76 | Issue: 2_Supplement | Pages: A03-A03

10.1158/1538-7445.chromepi15-a03 Get It

Abstract The Transforming Growth Factor-β (TGFβ)/SMAD signaling pathway can function as either a tumor suppressor or metastasis promoter during tumor progression. In normal epithelial cells and early stages of epithelial tumorigenesis TGFβ functions as a tumor suppressor to decrease cell proliferation or induce apoptosis. However, during malignant progression tumor cells no longer respond to the anti-proliferative effects of TGFβ, but instead undergo an epithelial-to-mesenchymal transition (EMT) whereby cells acquire a migratory and invasive phenotype which promotes tumor metastasis. Resolution of the dichotomy in TGFβ function and a further understanding of its tumor suppressor and metastasis promoting functions may uncover new strategies for the treatment of epithelial cancers. In previous studies we demonstrated an important role of the TGFβ-Inducible Early Gene-1 (TIEG1)/Krüppel-like Factor-10 (KLF10) as a central regulator of TGFβ/SMAD signaling and the anti-proliferative functions of TGFβ. In this study we examined the role of KLF10 in controlling the TGFβ-induced EMT in human lung adenocarcinoma cells. We show that depletion of KLF10 results in a more pronounced induction of EMT in human A549 lung adenocarcinoma cells as assessed by quantitative real-time PCR, changes in cellular morphology and immunofluorescence microscopy, and transcriptome-wide (RNA-seq) analyses. Moreover, chromatin immunoprecipitation (ChIP) and chromatin immunoprecipitation-sequencing (ChIP-seq) analysis shows that KLF10 directly binds to GC-rich sequences in the promoter region of the EMT-promoting transcription factor SLUG/SNAI2 to repress its transcription. Consistent with these findings, an analysis of KLF10 and SNAI2 expression in lung cancer revealed that while KLF10 levels are decreased in lung cancer vs. normal samples, SNAI2 levels are increased. Additional ChIP studies showed that KLF10 recruits HDAC1 to the SNAI2 promoter and is required for the removal of activating histone acetylation marks. These findings reveal a previously unknown function of KLF10 in suppressing TGFβ-induced EMT and represent a significant advancement in the understanding the molecular dichotomy of TGFβ function during tumor progression. Citation Format: Vivek Kumar Mishra, Vijayalakshmi Kari, Malayannan Subramaniam, Simon J. Baumgart, Sankari Nagarajan, Florian Wegwitz, Thomas C. Spelsberg, John R. Hawse, Steven A. Johnsen. Krüppel-like Transcription Factor-10 (KLF10) suppresses the TGFβ-induced epithelial-to-mesenchymal transition. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr A03.
Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors
Mondal, Sujan Kumar , Jinka, Sudhakar , Pal, Krishnendu , Nelli, Swetha, Dutta, Shamit K., Wang, Enfeng , Ahmad, Ajaz , Alkharfy, Khalid M. , Banerjee‬‬‬‬‬‬‬‬‬, Rintu , Dutta, Shamit Kumar, Mukhopadhyay, Debabrata , Pal, Krishnendu , Banerjee, Rajkumar

Mayo Clinic

Molecular Pharmaceutics | May 17, 2016 | Volume: 13 | Issue: 7 | Pages: 2507-2523

10.1021/acs.molpharmaceut.6b00230 | PMID 27184196 Get It

Spinal CSF venous fistula: A treatable etiology for CSF leaks in craniospinal hypovolemia
Kumar, Neeraj , Verdoorn, Jared T. , Garza, Ivan , Atkinson, John L. D., Diehn, Felix E. , Carr, Carrie M. , Luetmer, Patrick H. , Morris, Jonathan M.

Mayo Clinic

Neurology | May 14, 2016 | Volume: 86 | Issue: 24 | Pages: 2310-2312

10.1212/wnl.0000000000002776 | PMID 27178701 Get It

Clinical results of ultrasound bladder vibrometry for assessment of bladder compliance
Cheong, Mathew , Denis, Max , Gregory, Adriana , Nenadic, Ivan , Husmann, Douglas A. , Mynderse, Lance A. , Bayat, Mahdi , Kumar, Viksit , Mehrmohammadi, Mohammad , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

Journal of the Acoustical Society of America | May 6, 2016 | Volume: 139 | Issue: 4_Supplement | Pages: 2176-2176

10.1121/1.4950464 Get It

Healthy human bladder is a viscoelastic shell capable of expanding to allow storage of urine at low pressures. The ability to maintain low pressures as the urine volume increases is called bladder compliance. Compliance is a key in proper functioning of urinary system. Spinal cord injuries and other neurogenic diseases can cause deterioration in bladder expansion capability (e.g., through excessive growth of fibrotic tissue), which in turn can increase the rigidity of the wall and reduce bladder compliance. Urodynamic study (UDS) is the clinical standard for evaluation of the bladder compliance through observation of bladder pressure-volume behavior. However, this method is costly and invasive. Ultrasound bladder vibrometry (UBV) has been introduced as noninvasive technique for evaluation of bladder viscoelasticity through excitation of the bladder using ultrasound radiation force and tracking the resulting Lamb waves. Here, we present the results of UBV from 44 patients undergoing concurrent UDS and UBV studies. Our results show that elasticity parameters obtained from the UBV closely correlate with the UDS pressure-volume data with a median Pearson’s correlation value of more than 0.8. These results prove the potential utility of UBV as an alternative noninvasive method for bladder compliance assessment. [Work supported by NIH grant DK99231.]
Differentiation of breast lesions based on viscoelasticity response at sub-Hertz frequencies
Nabavizadeh, Alireza , Gregory, Adriana , Bayat, Mahdi , Kumar, Viksit , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

Journal of the Acoustical Society of America | May 6, 2016 | Volume: 139 | Issue: 4_Supplement | Pages: 2028-2028

10.1121/1.4949985 Get It

There is an urgent need for a noninvasive but more accurate method to assess breast masses before referring the patient to biopsy. In this study, we use the slow viscoelastic creep response to evaluate breast masses at low (<1 Hz) frequencies. This method uses an automated ramp-and-hold compression device and a high-frame-rate ultrasound imaging to track tissue strain. The study cohort included 30 pre-biopsy patients with suspicious masses. Sequential high-frame-rate images were recorded during the ramp-and-hold process. The data were used to calculate the creep response at each point. Then, using a classic linear model, the retardation-time map was created within the field of view. The resulting retardation-time maps exhibited clear distinction of the mass margins. The results showed that benign breast lesions appear with an increase in creep retardation-time compared to surrounding breast glandular tissue, and the opposite trend was true for the malignant lesions. Statistical analysis of the viscoelasticity features revealed that a contrast feature based on the retardation-time is an accurate classifier of malignant and benign masses (P<0.0003). It is concluded that the retardation time is a promising biomarker for differentiation of breast masses. [Work supported by NIH Grant CA168575.]
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light‐chain amyloidosis
Lacy, Martha Q. , Dispenzieri, Angela , Dingli, David , Hayman, Suzanne R. , Kumar, Shaji , Lust, John A., Russell, Stephen J. , Buadi, Francis K. , Lust, John, Le-Rademacher, Jennifer G., Gertz, Morie A. , Leung, Nelson , Rajkumar, S. Vincent , Suman, Vera J. , Le‐Rademacher, Jennifer , Hogan, William J. , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

Cancer | May 4, 2016 | Volume: 122 | Issue: 14 | Pages: 2197-2205

10.1002/cncr.30051 | PMID 27142462 Get It

BACKGROUNDAutologous stem cell transplantation (SCT) is a common management strategy for select patients with immunoglobulin light‐chain amyloidosis, but no trials have documented improved overall survival.METHODSEighty‐nine patients with biopsy‐proven immunoglobulin light‐chain amyloidosis were allowed to select treatment with melphalan plus dexamethasone (n = 34) or SCT (n = 55); all patients were transplant eligible. Treatment preference resulted in imbalanced study arms. Patients who selected SCT were younger, more frequently had an Eastern Cooperative Oncology Group performance status score less than 2, had lower‐stage amyloidosis, and had a lower incidence of cardiac amyloidosis.RESULTSPatients receiving melphalan plus dexamethasone had a 3‐year progression‐free survival rate of 29.1% and an overall survival rate of 58.8%. Patients undergoing SCT had a 3‐year progression‐free survival rate of 51.7% and an overall survival rate of 83.6%. An attempt to match patients between the 2 arms in terms of risk produced 24 matched triplet sets (2 SCT patients for each melphalan‐dexamethasone patient); there was no difference in hematologic response, but there was better survival after autologous SCT. A propensity score–matched analysis of the cohorts (melphalan plus dexamethasone vs SCT) showed an overall mortality hazard ratio of 2.56 (P < .01).CONCLUSIONSAlthough the study had limitations, similar hematologic responses and improved survival were observed after SCT versus melphalan plus dexamethasone. Cancer 2016;122:2197–205. © 2016 American Cancer Society.
Clinical neurocardiology defining the value of neuroscience‐based cardiovascular therapeutics
Shivkumar, Kalyanam , Ajijola, Olujimi A. , Anand, Inder S. , Armour, J. Andrew, Chen, Peng‐Sheng , Esler, Murray , Ferrari, Gaetano Maria De , Fishbein, Michael C. , Harper, Ronald M. , Joyner, Michael J. , Khalsa, Sahib S. , Lane, Richard D. , Mahajan, Aman , Po, Sunny S. , Valderrábano, Miguel , Vaseghi, Marmar , Goldberger, Jeffrey J , Kumar, Rajesh , Schwartz, Peter J. , Somers, Virend K. , Zipes, Douglas P. , Shivkumar, Kalyanam , Anand, Inder S , Joyner, Michael J , Khalsa, Sahib S

Mayo Clinic

The Journal of Physiology | April 27, 2016 | Volume: 594 | Issue: 14 | Pages: 3911-3954

10.1113/jp271870 | PMID 27114333 Get It

AbstractThe autonomic nervous system regulates all aspects of normal cardiac function, and is recognized to play a critical role in the pathophysiology of many cardiovascular diseases. As such, the value of neuroscience‐based cardiovascular therapeutics is increasingly evident. This White Paper reviews the current state of understanding of human cardiac neuroanatomy, neurophysiology, pathophysiology in specific disease conditions, autonomic testing, risk stratification, and neuromodulatory strategies to mitigate the progression of cardiovascular diseases.
Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C)
Swaika, Abhisek, Boczek, Nicole J. , Sood, Neha, Guthrie, Kimberly J., Klee, Eric W. , Dimberg, Elliot L., Guthrie, Kimberly, Agrawal, Ankit, Agrawal, Ankit Kumar , Ailawadhi, Sikander

Mayo Clinic

Case Reports in Genetics | April 19, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-4

10.1155/2016/9280812 | PMID 27195159 Get It

Dysferlinopathy is an uncommon, progressive muscular dystrophy that has a wide phenotypic variability and primarily supportive management (Nguyen et al., 2007; Narayanaswami et al., 2014). Amyloid myopathy is a distinct, rare disorder that can present similarly to inflammatory myopathies and requires a high clinical suspicion for early intervention to prolong survival. Amyloid myopathy is typically associated with other systemic manifestations of amyloidosis, but rare cases of isolated amyloid myopathy have been described (Mandl et al., 2000; Hull et al., 2001). Positive Congo red stains on tissue biopsy remain the gold standard for diagnosis (Spuler et al., 1998; Karacostas et al., 2005). A high clinical suspicion and meticulous diagnostic workup that includes novel techniques are necessary for identifying these rare disorders. We report a middle-aged man with progressive leg muscle weakness who was initially treated as having amyloid myopathy but was later diagnosed as having dysferlinopathy by Whole Exome Sequencing (WES) analysis. We also report a novel missense mutation (c.959G>C) to help correlate in any patient with presumed dysferlinopathy and to add to the already known genotype of this disorder.
An Unsusual Case of Lower Gastrointestinal Bleeding
Guru, Pramod , Iyer, Vivek , Guru, Pramod Kumar

Mayo Clinic

American Journal of Case Reports | April 12, 2016 | Volume: 17 | Issue: No issue available | Pages: 170-172

10.12659/ajcr.896511 | PMID 26979633 Get It

Type 2 Diabetes Mellitus Trajectories and Associated Risks
Oh, Won-Suk , Kim, Era, Castro, M. Regina , Kumar, Vipin , Steinbach, Michael , Simon, György , Caraballo, Pedro J. , Simon, Gyorgy J, Oh, Wonsuk

Mayo Clinic

Big Data | March 18, 2016 | Volume: 4 | Issue: 1 | Pages: 25-30

10.1089/big.2015.0029 | PMID 27158565 Get It